Table 3. Relationships between Serum ADAM 8 and Clinicopathological Characteristics of GC in Validation Dataset.
| Clinicopathological characteristics | Serum ADAM 8 [γs (p value)] |
|---|---|
| Age (yr)* | −0.064 (0.319) |
| Gender (male:female) | −0.095 (0.143) |
| Histology (well:mod:poorly:signet-ring)† | 0.139 (0.193) |
| Tumor location (lower:middle:upper) | 0.058 (0.397) |
| Tumor size (<3 cm; 3–5 cm and >5 cm)‡ | 0.121 (0.249) |
| T-stage (T1a:T1b:T2:T3:T4)§ | 0.197 (0.085) |
| N-stage (N0:N1:N2:N3)§ | 0.320 (0.011) |
| Distant metastasis (M0:M1)§ | 0.140 (0.193) |
ADAM 8, a disintegrin and metalloproteinase domain 8; GC, gastric cancer.
‘γs’ means ‘Spearman's correlation coefficient. p<0.05 (two-tailed) was considered statistically significant’.
*This was a continuous variable. Therefore, correlation was evaluated by Pearson's correlation (γp); †‘Well:mod:poorly:signet-ring’ means ‘well-differentiated carcinoma:moderate-differentiated carcinoma:poorly-differentiated carcinoma:signet-ring cell carcinoma’; ‡Tumor size was classified into three groups: <3 cm, 3–5 cm, and >5 cm; §TNM stage was evaluated according to the 7th International Union Against Cancer-TNM stage guidelines.